Answers are grounded in this paper and cite their sources.
Androgen deprivation therapy has an important role in the medical treatment of advanced and metastatic prostate cancer.The treatment of metastatic prostate cancer is influenced by whether the patient's disease has progressed on androgen deprivation therapy or not.It is considered to be castrate-resistant disease if the cancer has progressed despite adequate suppression of androgens.Chemotherapy using docetaxel or cabazitaxel and anti-androgen drugs such as abiraterone and enzalutamide can be used to treat castrate-resistant disease.Radium-223 is an option for patients with bony metastases.Metastatic castrate-resistant prostate cancer is now considered a chronic illness as the life expectancy of patients has almost doubled due to the new treatments.General practitioners are therefore more likely to encounter patients with disease-and treatment-related complications.delaying treatment until the onset of symptoms does not decrease overall survival.Either approach can be used.1 In patients with PSA relapse only (no overt metastases), intermittent therapy has been shown to be non-inferior to continuous dosing.There was also a better quality of life with intermittent dosing.4 In patients with objective metastases, intermittent androgen deprivation therapy had numerically worse outcomes than continuous treatment, but the study was statistically inconclusive.There was less sexual dysfunction and better mental health in the intermittent group, but this effect disappeared by 15 months when most people were back on continuous treatment.5 If shortterm quality of life is important, even at the risk of possible worse survival, intermittent therapy is a reasonable approach.
No takes yet. Share an insight, caveat, or question.
Body et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: